Mifepristone

Active ingredient: Mifepristone

In short: Mifepristone Tablets, 200 mg is indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.

Forms & strengthsTablets containing 200 mg of mifepristone each, supplied as 1 tablet on one blister card. Mifepristone tablets are light yellow coloured, round, biconvex tablets debossed with “CC12” on one side and plain on other side and free from physical defects.
LabelEvita Solutions LLC
Label updatedSep 08, 2026

What is Mifepristone used for?

Mifepristone Tablets, 200 mg is indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.

âš  Boxed warning (FDA's strongest warning)

Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following Mifepristone Tablets, 200 mg use. No causal relationship between the use of Mifepristone Tablets, 200 mg and misoprostol and these events has been established.

Atypical Presentation of Infection. Patients with serious bacterial infections (e.g.,

Clostridium sordellii) and sepsis can present without fever, bacteremia, or significant findings on pelvic examination following an abortion. Very rarely, deaths have been reported in patients who presented without fever, with or without abdominal pain, but with leukocytosis with a marked left shift, tachycardia, hemoconcentration, and general malaise. A high index of suspicion is needed to rule out serious infection and sepsis

Bleeding. Prolonged heavy bleeding may be a sign of incomplete abortion or other complications and prompt medical or surgical intervention may be needed. Advise patients to seek immediate medical attention if they experience prolonged heavy vaginal bleeding

.

Because of the risks of serious complications described above, Mifepristone Tablets, 200 mg is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Mifepristone REMS Program

.

Before prescribing mifepristone tablets, inform the patient about the risk of these serious events. …

Mifepristone dosage

For purposes of this treatment, pregnancy is dated from the first day of the last menstrual period. The duration of pregnancy may be determined from menstrual history and clinical examination. Assess the pregnancy by ultrasonographic scan if the duration of pregnancy is uncertain or if ectopic pregnancy is suspected.

Remove any intrauterine device (“IUD”) before treatment with Mifepristone Tablets, 200 mg begins

.

The dosing regimen for Mifepristone Tablets, 200 mg and misoprostol is:

Mifepristone Tablets, 200 mg orally + misoprostol 800 mcg buccally

•

Day One: Mifepristone Tablets, 200 mg Administration

One 200 mg tablets of Mifepristone is taken in a single oral dose.

•

Day Two or Three: Misoprostol Administration (minimum 24-hour interval between, Mifepristone Tablet, 200 mg and misoprostol)

Four 200 mcg tablets (total dose 800 mcg) of misoprostol are taken by the buccal route.

Tell the patient to place two 200 mcg misoprostol tablets in each cheek pouch (the area between the cheek and gums) for 30 minutes and then swallow any remnants with water or another liquid .

Patients taking Mifepristone Tablets, 200 mg must take misoprostol within 24 to 48 hours after taking Mifepristone Tablets. The effectiveness of the regimen may be lower if misoprostol is administered less than 24 hours or more than 48 hours after mifepristone administration.

Because most women will expel the pregnancy within 2 to 24 hours of taking misoprostol , discuss with the patient an appropriate location for them to be when taking the misoprostol, taking into account that expulsion could begin within 2 hours of administration.

During the period immediately following the administration of misoprostol, the patient may need medication for cramps or gastrointestinal symptoms

.

Give the patient:

Instructions on what to do if significant discomfort, excessive vaginal bleeding or other adverse reactions occur

A phone number to call if the patient has questions following the administration of the misoprostol

The name and phone number of the healthcare provider who will be handling emergencies.

Patients should follow-up with their healthcare provider approximately 7 to 14 days after the administration of Mifepristone Tablets, 200 mg. This assessment is very important to confirm that complete termination of pregnancy has occurred and to evaluate the degree of bleeding. Termination can be confirmed by medical history, clinical examination, human Chorionic Gonadotropin (hCG) testing, or ultrasonographic scan. Lack of bleeding following treatment usually indicates failure; however, prolonged or heavy bleeding is not proof of a complete abortion. …

How to take Mifepristone — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide), included with each package of Mifepristone Tablets, 200 mg. Additional copies of the Medication Guide are available by contacting Evita Solutions LLC at 1-866-718-0098 or

www.medicalabortionpill.com

Serious Infections and Bleeding

Inform the patient that uterine bleeding and uterine cramping will occur

.

Advise the patient that serious and sometimes fatal infections and bleeding can occur very rarely

.

Mifepristone Tablets, 200 mg are only available through a restricted program called the Mifepristone REMS Program

. Under the Mifepristone REMS Program:

Patients must sign a Patient Agreement Form.

Mifepristone Tablets, 200 mg is only dispensed by or under the supervision of certified prescribers or by certified pharmacies on prescriptions issued by certified prescribers.

Provider Contacts and Actions in Case of Complications

Ensure that the patient knows whom to call and what to do, including going to an emergency room if none of the provided contacts are reachable, or if the patient experiences complications including prolonged heavy bleeding, severe abdominal pain, or sustained fever

. …

Warnings & precautions

Do not take this medicine if: Administration of Mifepristone Tablets, 200 mg and misoprostol for the termination of pregnancy (the “treatment procedure”) is contraindicated in patients with any of the following conditions:

Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass (the treatment procedure will not be effective to terminate an ectopic pregnancy)

Chronic adrenal failure (risk of acute adrenal insufficiency)

Concurrent long-term corticosteroid therapy (risk of acute adrenal insufficiency)

History of allergy to mifepristone, misoprostol, or other prostaglandins (allergic reactions including anaphylaxis, angioedema, rash, hives, and itching have been reported

)

Hemorrhagic disorders or concurrent anticoagulant therapy (risk of heavy bleeding)

Inherited porphyrias (risk of worsening or of precipitation of attacks)

Use of Mifepristone Tablets, 200 mg and misoprostol for termination of intrauterine pregnancy is contraindicated in patients with an intrauterine device (“IUD”) in place (the IUD might interfere with pregnancy termination). If the IUD is removed, Mifepristone Tablets, 200 mg may be used.

As with other types of abortion, cases of serious bacterial infection, including very rare cases of fatal septic shock, have been reported following the use of Mifepristone Tablets, 200 mg

. Healthcare providers evaluating a patient who is undergoing a medical abortion should be alert to the possibility of this rare event. A sustained (> 4 hours) fever of 100.4°F or higher, severe abdominal pain, or pelvic tenderness in the days after a medical abortion may be an indication of infection.

A high index of suspicion is needed to rule out sepsis (e.g., from

Clostridium sordellii) if a patient reports abdominal pain or discomfort or general malaise (including weakness, nausea, vomiting or diarrhea) more than 24 hours after taking misoprostol. …

Mifepristone side effects

The following adverse reactions are described in greater detail in other sections:

Infection and sepsis

Uterine bleeding

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Information presented on common adverse reactions relies solely on data from U.S. studies, because rates reported in non-U.S. studies were markedly lower and are not likely generalizable to the U.S. population. In three U.S. clinical studies totaling 1,248 women through 70 days gestation who used mifepristone 200 mg orally followed 24 to 48 hours later by misoprostol 800 mcg buccally, women reported adverse reactions in diaries and in interviews at the follow-up visit. These studies enrolled generally healthy women of reproductive age without contraindications to mifepristone or misoprostol use according to the Mifepristone Tablets, 200 mg product label.Gestational age was assessed prior to study enrollment using the date of the woman's last menstrual period, clinical evaluation, and/or ultrasound examination.

About 85% of patients report at least one adverse reaction following administration of Mifepristone Tablets, 200 mg and misoprostol, and many can be expected to report more than one such reaction. …

Drug interactions

CYP450 3A4 is primarily responsible for the metabolism of mifepristone. CYP3A4 inducers such as rifampin, dexamethasone, St. John's Wort, and certain anticonvulsants (such as phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum concentrations of mifepristone). Whether this action has an impact on the efficacy of the dose regimen is unknown. Refer to the follow-up assessment

to verify that treatment has been successful.

Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug's metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum concentrations of mifepristone). Mifepristone Tablets, 200 mg should be used with caution in patients currently or recently treated with CYP 3A4 inhibitors.

Based on

in vitroinhibition information, coadministration of mifepristone may lead to an increase in serum concentrations of drugs that are CYP 3A4 substrates. Due to the slow elimination of mifepristone from the body, such interaction may be observed for a prolonged period after its administration. …

About this medicine

Mifepristone tablets each contain 200 mg of mifepristone, a synthetic steroid with antiprogestational effects. The tablets are light yellow coloured, round, biconvex, debossed with “CC12” on one side, plain on other side and free from physical defects and are intended for oral administration only. The tablets include the inactive ingredients colloidal silicon dioxide, maize starch, povidone, microcrystalline cellulose, and magnesium stearate.

Mifepristone is a substituted 19-nor steroid compound chemically designated as 11Ăź-[

p- (Dimethylamino) phenyl]-17Ăź-hydroxy- 17-(1-propynyl) estra-4,9-dien-3-one. Its empirical formula is C

29H

35NO

2. Its structural formula is:

The compound is a yellow powder with a molecular weight of 429.6 and a melting point of 192 to 196°C. It is very soluble in methanol, chloroform and acetone and poorly soluble in water, hexane and isopropyl ether.

How it works: The anti-progestational activity of mifepristone results from competitive interaction with progesterone at progesterone-receptor sites. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 839d7a7d-de19-42bd-8810-132b3c2a5daf. Read the full official label on DailyMed.